TrialThe Lancet. Respiratory medicine2023

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.

Nicole Mayer-Hamblett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.